JP7546603B2 - タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 - Google Patents

タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 Download PDF

Info

Publication number
JP7546603B2
JP7546603B2 JP2021568650A JP2021568650A JP7546603B2 JP 7546603 B2 JP7546603 B2 JP 7546603B2 JP 2021568650 A JP2021568650 A JP 2021568650A JP 2021568650 A JP2021568650 A JP 2021568650A JP 7546603 B2 JP7546603 B2 JP 7546603B2
Authority
JP
Japan
Prior art keywords
mmol
ripk3
pyrimidin
yield
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021568650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533182A5 (https=
JP2022533182A (ja
JPWO2020232190A5 (https=
Inventor
グレゴリー クニー
アレクセイ デグテレヴ
サメール ニカール
シドハース バラチャンドラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of JP2022533182A publication Critical patent/JP2022533182A/ja
Publication of JP2022533182A5 publication Critical patent/JP2022533182A5/ja
Publication of JPWO2020232190A5 publication Critical patent/JPWO2020232190A5/ja
Priority to JP2024145040A priority Critical patent/JP2024170457A/ja
Application granted granted Critical
Publication of JP7546603B2 publication Critical patent/JP7546603B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021568650A 2019-05-16 2020-05-14 タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 Active JP7546603B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024145040A JP2024170457A (ja) 2019-05-16 2024-08-27 タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962848648P 2019-05-16 2019-05-16
US201962848719P 2019-05-16 2019-05-16
US62/848,648 2019-05-16
US62/848,719 2019-05-16
PCT/US2020/032784 WO2020232190A1 (en) 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024145040A Division JP2024170457A (ja) 2019-05-16 2024-08-27 タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用

Publications (4)

Publication Number Publication Date
JP2022533182A JP2022533182A (ja) 2022-07-21
JP2022533182A5 JP2022533182A5 (https=) 2023-05-02
JPWO2020232190A5 JPWO2020232190A5 (https=) 2023-05-02
JP7546603B2 true JP7546603B2 (ja) 2024-09-06

Family

ID=70919255

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568650A Active JP7546603B2 (ja) 2019-05-16 2020-05-14 タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用
JP2024145040A Pending JP2024170457A (ja) 2019-05-16 2024-08-27 タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024145040A Pending JP2024170457A (ja) 2019-05-16 2024-08-27 タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用

Country Status (6)

Country Link
US (1) US12516055B2 (https=)
EP (2) EP4480485A3 (https=)
JP (2) JP7546603B2 (https=)
AU (1) AU2020275304B2 (https=)
CA (1) CA3137869A1 (https=)
WO (1) WO2020232190A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024170457A (ja) * 2019-05-16 2024-12-10 ユニバーシティー オブ ヒューストン システム タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174255B2 (en) * 2017-05-15 2021-11-16 University Of Houston System Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
CN113072471B (zh) * 2021-03-02 2022-09-16 四川美大康华康药业有限公司 一种利非司特中间体及其制备方法
WO2024097805A1 (en) * 2022-11-01 2024-05-10 Trustees Of Tufts College Mixed lineage kinase domain like pseudokinase (mlkl) activators
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515078A (ja) 1997-08-20 2001-09-18 ワーナー−ランバート・カンパニー プロテインチロシンキナーゼおよび細胞周期キナーゼ仲介細胞増殖を阻害するためのナフチリジノン
JP2003523358A (ja) 2000-01-27 2003-08-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 神経変性疾患の治療のためのピリドピリミジノン誘導体
WO2014031571A1 (en) 2012-08-21 2014-02-27 Icahn School Of Medicine At Mount Sinai Treatment of viral infections
WO2015179436A1 (en) 2014-05-19 2015-11-26 Sanford-Burnham Medical Research Institute Inflammation therapy using mekk3 inhibitors or blocking peptides
WO2018213219A1 (en) 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
EP4480485A3 (en) * 2019-05-16 2025-02-26 University of Houston System Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515078A (ja) 1997-08-20 2001-09-18 ワーナー−ランバート・カンパニー プロテインチロシンキナーゼおよび細胞周期キナーゼ仲介細胞増殖を阻害するためのナフチリジノン
JP2003523358A (ja) 2000-01-27 2003-08-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 神経変性疾患の治療のためのピリドピリミジノン誘導体
WO2014031571A1 (en) 2012-08-21 2014-02-27 Icahn School Of Medicine At Mount Sinai Treatment of viral infections
WO2015179436A1 (en) 2014-05-19 2015-11-26 Sanford-Burnham Medical Research Institute Inflammation therapy using mekk3 inhibitors or blocking peptides
WO2018213219A1 (en) 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THOMPSON,A.M. et al.，Synthesis and Structure-Activity Relationships of 7-Substituted 3-(2,6-Dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as Selective Inhibitors of pp60c-src，Journal of Medicinal Chemistry，2000年，Vol.43, No.16，p.3134-3147

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024170457A (ja) * 2019-05-16 2024-12-10 ユニバーシティー オブ ヒューストン システム タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用

Also Published As

Publication number Publication date
EP4480485A3 (en) 2025-02-26
US20220194937A1 (en) 2022-06-23
US12516055B2 (en) 2026-01-06
AU2020275304B2 (en) 2025-01-23
AU2020275304A1 (en) 2021-12-16
JP2022533182A (ja) 2022-07-21
WO2020232190A1 (en) 2020-11-19
EP3968991B1 (en) 2024-07-31
CA3137869A1 (en) 2020-11-19
EP3968991A1 (en) 2022-03-23
EP3968991C0 (en) 2024-07-31
JP2024170457A (ja) 2024-12-10
EP4480485A2 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
JP7546603B2 (ja) タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用
KR101530117B1 (ko) 야누스 키나제 억제제 화합물 및 방법
CN109071514B (zh) 用作蛋白质调节剂的杂环酰胺
TWI433677B (zh) 雜環化合物及其用途
TWI659021B (zh) Ｋｒａｓ ｇ１２ｃ之抑制劑
AU2021282986B2 (en) LPA receptor antagonists and uses thereof
US9567342B2 (en) Certain protein kinase inhibitors
WO2021143701A1 (zh) 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
CN106488910A (zh) Kras g12c的抑制剂
RS63603B1 (sr) Sredstva za indukciju apoptoze
CN105555786A (zh) 作为BET蛋白和极体样激酶的双重抑制剂的取代的二氢吡啶并[3,4-b]吡嗪酮
CN100439365C (zh) 用作蛋白激酶抑制剂的化合物和组合物
US20240327403A1 (en) PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
CN110997657A (zh) 咪唑烷化合物
TW201712011A (zh) 作為ｂｅｔ家族溴結構域抑制劑之新穎吡啶吡酮
KR20150103672A (ko) 나프티리디논 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도
WO2020114519A1 (zh) 作为cdk-hdac双通路抑制剂的杂环化合物
WO2015193228A1 (de) Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
CN111205281B (zh) 杂环化合物及其用途
JP2024536861A (ja) 伝染性軟属腫感染症の阻害剤およびそれを用いる方法
KR20240115270A (ko) 사이클린 의존성 키나아제의 새로운 억제제
US20260097029A1 (en) Tetrahydroquinoline Compounds As Antitumor Agents
ES3058769T3 (en) Novel triazolopyridine derivative and pharmaceutical composition comprising same
HK40082693B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
CN119698277A (zh) 作为治疗剂的cGAS活性抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230424

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240724

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240827

R150 Certificate of patent or registration of utility model

Ref document number: 7546603

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150